



BIOTHÉRAPIE INNOVATION OCCITANIE

Biotherapy and biomanufacturing:
the integrated offer in Occitanie



STRATÉGIE RÉGIONALE
DE L'INNOVATION
OCCITANIE





Occitanie Innovation Biotherapy is a collaborative strategy centred on the biotherapy and bioproduction economic sectors. It unites various regional, academic, and industrial stakeholders across the value chain, with goals to:

- Create a unique, agile and effective integrated scientific and industrial ecosystem to promote and accelerate the discovery, bioproduction, and commercialization of biotherapeutic drugs.
- Strengthen regional bioproduction capabilities.
- Bring stakeholders together around ambitious joint projects, improving the identification of expertise and its complementary nature.
- Boost visibility in this growing sector and elevate regional expertise in France and globally.

Occitanie Innovation Biotherapy is overseen by AD'OCC, the Region's economic development agency, along with Eurobiomed, the competitiveness cluster, and industrial and academic representatives from the sector.

Contact:
biotherapie@agence-adocc.com

More information:



Comprehensive
training



page 6

Academic
excellence



page 6

Innovation
accelerator



page 7

A strong innovation ecosystem


60 industrial and 40 academic players across the entire

Cutting-edge
expertise with 3
university hospitals
and 2 comprehensive
cancer centers



pages 8 - 9

Biomanufacturing



pages 10 - 11

summary

> page 13

value chain > pages 14 - 15



Bio'Occ

The Biotherapy and Bioproduction in Occitanie (Bio'Occ) project aims to structure a clear and attractive training program that meets the needs of the region. Bio'Occ plans to train more than 1,000 graduates (from pre-baccalaureate to PhD level) over five years and to raise awareness of careers in bioproduction and biotherapies among students, professionals, and employers. It also carries out awareness-raising activities on the challenges facing this sector, which is strategic for the future of healthcare.

Contact:

bio-occ.contact@utoulouse.fr

More information:



CeBBOc
Cell Based Biotherapies Occitanie

The CeBBOc (Cell Based Biotherapies Occitanie) project, led by Inserm, aims to structure and strengthen regional academic multidisciplinary players around cell-based biotherapies, drawing on the expertise of Inserm and its laboratories in Occitanie. The project aims to accelerate the development of cell and gene therapies, while consolidating regional infrastructures dedicated to the bioproduction of biomedicines.

Contact:

défi-clé-biotherapie-occitanie@inserm.fr

More information:





OBBI (Occitanie Biotherapy-Bioproduction Integrator) is the only french integrator structure recognized at the national level aiming to strengthen the industrialization of extracellular vesicles (EVs) and organoids bioproduction by supporting stakeholders in the development, optimization, and scaling up of their bioprocesses. OBBI thus acts as a strategic lever to structure the regional sector and facilitate collaboration between research, industry, and support structures.

Contact:

obbi.integrator@inserm.fr

More information:



The TIBH (Toulouse Industrial Biotechnology for Health) integrator was born out of the synergy between TWB (Toulouse White Biotechnology), CRITT Bio-Industries, and TBI (Toulouse Biotechnology Institute). Its goal is to structure and accelerate the development of bioprocesses by facilitating the transfer of biotechnological innovations to industry. It aims to develop alternatives to conventional bioproduction by using microbial cell factories and developing suitable, low-cost bioprocesses.

Contact:

tibh@insa-toulouse.fr

More information:





INSTITUT UNIVERSITAIRE
DU CANCER DE TOULOUSE
Unicopole

Three university hospitals (CHUs), which are leading institutions in the fields of healthcare, teaching, and research: the Nîmes University Hospital, the Montpellier University Hospital, and the Toulouse University Hospital.

Two Comprehensive Cancer Centers - CLCC - which are establishments that guarantee equal access to care for all patients, a multidisciplinary medical and care approach, as well as comprehensive patient care. In Occitanie: the Montpellier Cancer Institute (ICM) and The Toulouse University Cancer Institute (IUCT).



The University Hospital Institute, supported by Montpellier University Hospital, INSERM, and the University of Montpellier, aims to accelerate research and development of new therapies in the field of autoimmune diseases by strengthening university hospital infrastructure and promoting synergies between fundamental research, clinical innovation, and bioproduction.

More information:



Specific features of Toulouse University Hospital in the field of biotherapies:

The Biotherapies module of the Clinical Investigation Center at Toulouse University Hospital is entirely dedicated to research into biotherapies (cell and gene therapies alone or combined with biomaterials, monoclonal antibodies) for adult patients.

Contacts:

Fabian GROSS

gross.f@chu-toulouse.fr

Marine LEBRIN

lebrin.m@chu-toulouse.fr

More information:



The HealthAge University Hospital Institute is a translational research institute dedicated to the prevention of ageing, healthy longevity, and geroscience, at the forefront of innovation and ageing care by strengthening the six essential functions (vision, hearing, memory, psychological well-being, mobility, and vitality), also known as intrinsic capacities, thereby extending healthy life expectancy.

Contact:

contact-ihuhealthage@chu-toulouse.fr

More information:





The LFB is a biopharmaceutical group that develops, manufactures, and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases. Its mission is to offer new treatment options for patients in three major therapeutic areas: immunology, hemostasis, and intensive care. LFB currently markets 15 biopharmaceutical products in around thirty countries.

LFB BIOMANUFACTURING is a company within the LFB Group and one of the key entities in the Group's pharmaceutical bioproduction activities. The industrial site in Alès, has an extensive expertise in the manufacturing of recombinant proteins and monoclonal antibodies from mammalian cell culture: from cell line and process development to GMP-manufacturing (clinical and commercial batches).

More information:



OLON France have an expertise in process development and both non-GMP and GMP production of antibodies, proteins, and bioconjugates. Utilizing advanced mammalian and microbial expression platforms, they deliver fully tailored solutions for a broad spectrum of biologics—including complex, hard-to-express molecules such as bispecific antibodies and antibody-drug conjugates (ADCs).

More information:





CELL-EASY is a Cell Therapy specialized CDMO, supporting Biotechs, Pharmas & public institutions in the Development & GMP Manufacturing of Advanced therapies. Their mission: accelerate the Cell Therapy's path to market, with patient access in mind.

The team brings hands-on expertise in cell culture across all cell types, engineered or not, addressing challenges in development, GMP manufacturing, and QC. Beyond core CDMO services—process diagnostics, development, GMP production, cell banking, cryostorage, and delivery — they also support sourcing of human biological materials and clinical trial setup, helping you move efficiently from concept to clinic.

More information:



Inits SMO (Shared Manufacturing Organization) is a flexible biomanufacturing unit, allowing biotech companies to implement their innovative processes and conduct from R&D to GMP production themselves with INITS' support

Inits offers personalized services from drug development to clinical trials, with expertises that includes CMC (Chemistry, Manufacturing and Controls), Regulatory, IMP (Investigational Medicinal Product) and QA (Quality Assurance) management and support.

More information:





SANOFI WINTHROP INDUSTRIE ARAMON

The Aramon site is a pharmaceutical chemistry industrial facility. The site's production is organized to meet clear and ambitious objectives: employee safety, customer satisfaction, compliance with GMP, environmental protection, economic performance, and preparing the site's future by working on the integration of new active pharmaceutical ingredients. Aramon is certified by the world's major health authorities for the production of its active ingredients.

The site realizes the production of recombinant proteins from fermentation or purification of biological media.

More information:




ID BIOPROD is a service provider specialized in bioprocess engineering (fermentation and downstream). They accompany biotech companies in the development of innovative bioprocesses or bioproducts, providing support from lab scale development to industrial production. Their expertises include :

- Cultivating a wide range of microbial organisms (yeast, bacteria, fungi, BSL1, BSL2, GMO, aerobic or anaerobic microorganisms),
- Developing high cell-density processes,
- Optimizing the production of intracellular and extracellular molecules,
- Developing a wide variety of fermentation processes: batch/fed batch/chemostat.

More information:





Industrial players from Occitanie

	Cell therapy	Gene therapy	Antibody and Proteins	Gene delivery and targeting technologies
Biotech companies	<ul style="list-style-type: none"> · Cilcare · Ciloa · Emercell · Ingraalys · Innomune Therapeutics · NBX Biosciences · NK diagnostics · Orega Biotech · Organips · Pierre Fabre · Regenlife · RNAlead · Symbioken 	<ul style="list-style-type: none"> · Cilcare · Medesis · Lymphtech · Nervosave Therapeutics · RNAlead · Sensorion 	<ul style="list-style-type: none"> · Abionyx Pharma · Aken Medical · Arthritis for cure · Ciloa · Dolinnov · G.Clips biotech · Gamamabs · Mabqi · Orega biotech · Pierre Fabre · Spima Therapeutics · Spima Therapeutics · Surgimab 	<ul style="list-style-type: none"> · Divincell · Nanomedsyn · RNAlead · Specific Polymers
CRO	<ul style="list-style-type: none"> · Ambiotis · Cell-Easy · Diva Expertise · Enterosys · Genoskin · Human Cell Design · Icelltis · Screening & Fluidics · Stem Genomics · Urosphere 	<ul style="list-style-type: none"> · Ambiotis · Enterosys · Genoskin 	<ul style="list-style-type: none"> · Enterosys · G.Clips biotech · Genoskin · Screening & Fluidics · Imactiv 3D · Phylogene · Quantacell · Synaxys · Vaioomer · Vibiosphen 	<ul style="list-style-type: none"> · Predictcan Biotechnologies · Neovirtech
Biomanufacturing	<ul style="list-style-type: none"> · Cell-Easy · Inits SMO 	<ul style="list-style-type: none"> · Inits SMO 	<ul style="list-style-type: none"> · ID Bioprod · Inits SMO · LFB · Biomanufacturing · Olon France · Sandoz · Sanofi Winthrop 	
Providers of specialized technologies		<ul style="list-style-type: none"> · Adelis · Bionomeex · Indatech · Iprasense · NewTec Scientific · Ondalys · Quantacell · Stem Genomics 		

Academic players from Occitanie

	Cell therapy	Gene therapy	Antibody and Proteins	Tissue engineering
R&D	<ul style="list-style-type: none"> · CRCT · I2MC · IBMM · ICGM · ICM · IGF · IGH · IGMM · INFINITY · INM · IRMB · IRSD · IUCT · LABHPEC · LBN · LTCD · PHYMEDEXP · RESTORE · SAFE IPS · TONIC 	<ul style="list-style-type: none"> · CEA - NanO'up · CRBM · CRCT · I2MC · IBMM · ICM · IGF · IGMM · INFINITY · INM · IRMB · IUCT · TIBH 	<ul style="list-style-type: none"> · BACFLY · CBS · CRBM · CRCT · IBMM · IGF · IGH · INFINITY · IPBS · IRCM · IRMB · IRSD · LCC · LMGM · TIBH 	<ul style="list-style-type: none"> · CBS · CIRIMAT · I2MC · IBMM · ICGM · IGF · INFINITY · IPBS · IRMB · IRSD · L2C · LAAS · LBN · PHYMEDEXP · RESTORE · RHEM · SOFTMAT · TONIC
Industrialization / Biomanufacturing	<ul style="list-style-type: none"> · IRMB · LTCD · OBBI · SAFE IPS 	<ul style="list-style-type: none"> · CEA - NanO'up · TIBH 	<ul style="list-style-type: none"> · BACFLY · TIBH 	<ul style="list-style-type: none"> · OBBI
Clinical development	<ul style="list-style-type: none"> · CHU Montpellier · CHU Toulouse · CIC Biothérapies · ICM · INM · IRMB · IUCT · LABHPEC · RESTORE · TONIC 	<ul style="list-style-type: none"> · CEA - NanO'up · CHU Montpellier · CHU Toulouse · CIC Biothérapies · ICM · INM · IUCT 	<ul style="list-style-type: none"> · CHU Montpellier · CHU Toulouse · ICM · IUCT 	<ul style="list-style-type: none"> · CIC Biothérapies · CIRIMAT · IRMB · TONIC



agence-adocc.com/biotherapie-innovation-occitanie/ x

biotherapie@agence-adocc.com



STRATÉGIE RÉGIONALE
DE L'INNOVATION
OCCITANIE



Cofinancé par
l'Union européenne